gemcitabine,cisplatin,carboplatin,enfortumab,pembrolizumab
astellas,seagen,merck
['bladder', 'pembro', 'ev103']
ev103 presented by . 45 patients with upfront ev and pembro for bladder cancer. 15%cr rate by bicr exciting. would be interesting to see if this holds up in real world as it has fda accel approval already. #asco23
A medical oncologist that specializes in and focuses his research on urologic cancers.